0001193125-26-082630
SEC filingInogen, Inc. (INGN) reported FY 2025 total revenue of $348.7M, up 3.9% YoY from $335.7M in 2024, driven by 5.9% growth in sales revenue to $295.3M from higher international demand (39.8% of total, up 18.4% YoY). U.S. sales declined 3.1% to $156.5M due to channel mix shifts, while rental revenue fell 6.3% to $53.4M from lower patient volumes and reimbursement pressures. Gross profit dipped slightly to $154.3M (44.2% margin vs. 46.1% YoY) due to higher component costs and warranty mix. Net loss narrowed to $22.7M from $35.9M, aided by $5.4M lower sales/marketing and $5.2M reduced G&A expenses. Operating cash flow was negative $11.2M vs. positive $5.9M prior year, reflecting earnout payments and working capital changes. Balance sheet strengthened with $103.7M cash, $15.8M marketable securities, and $192.2M equity; total assets $298.6M. Strategic focus on international expansion, Simeox U.S. launch, and Yuwell partnership positions Inogen for respiratory market growth amid reimbursement and supply chain risks.
Inogen's FY 2025 revenue reached $348.7M, a 3.9% YoY increase from $335.7M, with sales revenue up 5.9% to $295.3M and rentals down 6.3% to $53.4M. Gross profit was $154.3M (44.2% margin, down from 46.1%), reflecting higher costs. Operating expenses declined to $184.5M from $197.3M, driving net loss improvement to $22.7M (vs. $35.9M). Cash from financing included $27.2M from Yuwell equity; operating cash used $11.2M. Balance sheet shows $298.6M assets, $192.2M equity.
Sales revenue grew to $295.3M (+5.9% YoY), with international at $138.8M (39.8% of total, +18.4% YoY, Europe 85%). U.S. sales $156.5M (-3.1% YoY) due to channel shifts. Rentals $53.4M (-6.3% YoY) from fewer patients and reimbursement mix. U.S. revenue $209.8M (45.1% HME/distributors, 29.5% DTC sales, 25.4% DTC rentals). Growth driven by 189,400 units sold vs. 157,500 prior year.
Sales gross margin 44.5% (down from 46.7%) due to component premiums and warranty; rental 42.7% (from 43.3%). Total margin 44.2%. R&D $19.4M (5.6% revenue, -10.2% YoY), sales/marketing $97.7M (28.0%, -5.2% YoY), G&A $67.4M (19.3%, -7.2% YoY). Adjusted EBITDA $2.7M vs. -$9.5M prior year.
Operating cash -$11.2M (vs. +$5.9M), investing -$26.2M (acquisition $29.6M prior), financing +$24.2M. Cash $103.7M, marketable securities $15.8M, total liquidity supports 12+ months. Current assets $198.3M, liabilities $63.5M, net working capital $134.8M (up from $108.8M). Total liabilities $106.4M, equity $192.2M.
Cash sufficient for 12+ months; focus on international growth, Simeox commercialization, Voxi/Aurora launches via Yuwell. Risks: reimbursement changes, supply chain, competition. Continued R&D investment; no dividends planned.